Travere Therapeutics TVTX
NASDAQ TVTX
$52.38 +0.34 (+0.66%)
As of: Nov 12, 2026 · 11:53 AM EST

Travere Therapeutics (TVTX) Return on Sales [ROS] (2013 - 2026)

Updated

Travere Therapeutics (TVTX) recorded Return on Sales [ROS] of -30.33% in Q3 2026, down 45.45 percentage points from 15.12% a year earlier and down 32.66 percentage points from the prior quarter.

Analysis

Travere Therapeutics (TVTX) Return on Sales [ROS] (2013 - 2026) Analysis & Trends

On a TTM basis, Travere Therapeutics' Return on Sales [ROS] came in at -20.50% as of Sep 30, 2026, up 0.40 percentage points year-over-year; for FY2025, it came in at -12.80%, up 126.08 percentage points from FY2024.

  • Annual Return on Sales [ROS] has increased for three straight years, with a five-year change of +76.03 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -138.88% in FY2024 (+128.37 pp), -267.24% in FY2023 (+24.93 pp) and -292.17% in FY2022.
  • The Q3 2026 figure is the lowest quarterly Return on Sales [ROS] since Q1 2025.
  • On a year-over-year basis, Return on Sales [ROS] rose in seven of the last eight quarters, with an average year-over-year change of +84.75 percentage points.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 411.57 percentage points in Q4 2022, against a drop of 474.55 percentage points in Q4 2021 at the low end.
  • Per Business Quant, the preceding three quarters came in at 2.33% (Q2 2026), -29.02% (Q1 2026) and -25.00% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Travere Therapeutics 4.97 Bn 4.56 Bn 221.70 Mn -30.33%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -30.33%
Jun 30, 2026 2.33%
Mar 31, 2026 -29.02%
Dec 31, 2025 -25.00%
Sep 30, 2025 15.12%
Jun 30, 2025 -11.05%
Mar 31, 2025 -52.21%
Dec 31, 2024 -81.21%
Sep 30, 2024 -89.27%
Jun 30, 2024 -125.11%
Mar 31, 2024 -336.53%
Dec 31, 2023 -209.13%
Sep 30, 2023 -249.59%
Jun 30, 2023 -322.87%
Mar 31, 2023 -315.23%
Dec 31, 2022 -295.52%
Sep 30, 2022 -294.23%
Jun 30, 2022 -274.24%
Mar 31, 2022 -307.45%
Dec 31, 2021 -707.08%
API Access

Travere Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=TVTX&period=max&api_key=YOUR_API_KEY